The four antiherpes compounds acyclovir, adenine arabinoside, bromovinyldeoxyuridine, and phosphonoformic acid showed an additive to synergistic effect with human leukocyte interferon in inhibiting focus formation by three different strains of varicella-zoster virus in human embryonic fibroblasts.
The four antiherpes compounds acyclovir, adenine arabinoside, bromovinyldeoxyuridine, and phosphonoformic acid showed an additive to synergistic effect with human leukocyte interferon in inhibiting focus formation by three different strains of varicella-zoster virus in human embryonic fibroblasts.
Varicella-zoster virus (VZV) is the causative agent of chickenpox (varicella) and shingles (herpes zoster). These are normally self-resolving diseases, but they are often severe and occasionally fatal in immunocompromised patients. We have recently examined several newly developed antiherpes compounds for their inhibitory effects on focus formation by VZV in vitro (9) . The compounds varied widely in their potency and selectivity as anti-VZV agents, one of the most potent and selective being bromovinyldeoxyuridine (BVDU) . Other well-known antiherpes drugs such as acyclovir (ACV), adenine arabinoside (ara-A), and phosphonoformic acid (PFA) proved less potent and less selective in their anti-VZV activity than BVDU did (2, 9).
Combinations of antiviral drugs are of interest because of their potential for increasing efficacy or reducing toxicity or both. Combinations of a number of agents, including ara-A and ACV (1, 6, 7, 11), have been evaluated against herpes simplex virus type 1 and type 2 in vitro. Combinations of antiviral agents at nontoxic concentrations usually result in synergistic, additive, subadditive, or indifferent effects, but rarely in antagonistic effects. Combinations including ACV generally result in an additive effect against VZV (3). ACV in combination with human interferon displays additive to synergistic effects against herpes simplex virus type 1 and type 2 (8, 10) . In the present study, we examined the activities of combinations of human leukocyte interferon (HuIFN-a) with ACV, ara-A, PFA, or BVDU against VZV.
The sources of the antiherpes compounds were as follows: Three VZV strains were used. The CaQu strain was kindly provided by N. J. Schmidt, Viral and Rickettsial Disease Laboratories, Department of Health, Berkeley, Calif. The Hirai and Tokumaru strains were isolated in our laboratory from patients with herpes zoster and were passaged several times in human embryo fibroblast (HEF) cultures. All VZV strains were prepared as cell-free virus and were stored at -80°C until used. Antiviral assays were carried out in confluent HEF monolayers in Linbro multiwell plates with * Corresponding author.
24 flat-bottom wells (16-mm diameter). HEF cell cultures were propagated in Eagle minimal essential medium supplemented with 10% heat-inactivated fetal calf serum, 100 ,ug of streptomycin per ml, and 100 U of penicillin G per ml. After 3 days of cultivation, the HEF cultures were exposed for 24 h to various concentrations of HuIFN-a (0.25, 0.5, 1, 2, 4, 8, and 16 IU/ml) in maintenance medium (Eagle minimal essential medium containing 2% fetal calf serum and antibiotics at the concentrations mentioned above). After the HuIFN-a treatment, the HEF cultures were washed thoroughly with maintenance medium, infected with ca. 50 PFU of VZV (multiplicity of infection, 5 x 10-4), and immediately thereafter exposed to various concentrations of the compounds (BVDU, 0.0025, 0.005, 0.01, 0.02, and 0.04 ,g/ml; ACV or ara-A, 0.25, 0.5, 1, 2, and 4 ,ug/ml; PFA, 5, 10, 20, 40, and 80 ,ug/ml) in maintenance medium. Foci were counted microscopically at 3 days after virus infection without fixation and staining of cells. Dose-response curves for all antiviral compounds were set up in combination with various concentrations of HuIFN-a, and the concentration of compound (or HuIFN-a) required to reduce the number of foci to 30% of that in the control cell cultures (infected with VZV but not exposed to either antiviral compound or HuIFN-a) was chosen as the endpoint of antiviral activity. When focus reduction was not exactly 30% of the control, the endpoint concentration was obtained by plotting the number offoci as a function of the compound concentration (Fig. 1 ). Data were plotted and analyzed by the isobologram method (5). The fractional inhibitory concentration (FIC) for each pair, i.e., compound x plus HuIFN-a, was calculated as follows: FICX = (concentration of x in the combination at the endpoint)/(concentration of x alone required to achieve that endpoint) and FICIF = (concentration of HuIFN-a in the combination at the endpoint)/(concentration of HuIFN-ai alone required to achieve that endpoint). Combinations resulting in additive antiviral (FIC, + FICIF = 1) are represented by straight lines (unity lines) on the isobolograms (dotted in Fig. 2) . When the combination resulted in synergy, a stronger antiviral effect than the sum of the individual effects (FIC, + FICIF < 1), the representational line shifts below the unity line. When the combination resulted in antagonistic activity (FICx + FICIF > 1), the line shifts above the unity line.
The dose-response curves for the different antiherpes compounds are shown in Fig. 1 . All compounds effected a significantly greater reduction in VZV focus formation after combination with HuIFN-a. Experiments similar to that shown for the CaQu strain (Fig. 1) 
